Structure Therapeutics Inc. Retained Earnings
Structure Therapeutics Inc. (GPCR) had Retained Earnings of -$652.43 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-06
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$652.43M.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$546.27M.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$470.30M.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$503.30M.
| Period end | Retained Earnings (Accumulated Deficit) |
|---|---|
| 2026-06-30 | -$652.43M 10-Q · filed 2026-08-06 |
| 2026-03-31 | -$546.27M 10-Q · filed 2026-05-07 |
| 2025-12-31 | -$470.30M 10-Q · filed 2026-08-06 |
| 2025-09-30 | -$503.30M 10-Q · filed 2025-11-06 |
| 2025-06-30 | -$437.59M 10-Q · filed 2025-08-06 |
| 2025-03-31 | -$375.93M 10-Q · filed 2025-05-08 |
| 2024-12-31 | -$329.10M 10-K · filed 2026-02-26 |
| 2024-09-30 | -$292.62M 10-Q · filed 2024-11-13 |
| 2024-06-30 | -$258.64M 10-Q · filed 2024-08-08 |
| 2024-03-31 | -$232.61M 10-Q · filed 2024-05-09 |
| 2023-12-31 | -$206.57M 10-K · filed 2025-02-27 |
| 2023-09-30 | -$182.07M 10-Q · filed 2023-11-17 |
| 2023-06-30 | -$158.21M 10-Q/A · filed 2023-11-17 |
| 2023-03-31 | -$134.93M 10-Q · filed 2023-05-11 |
| 2022-12-31 | -$116.95M 10-K · filed 2024-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |